<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="50848"><DrugName>tiprelestat</DrugName><DrugNamesKey><Name id="42929953">tiprelestat</Name></DrugNamesKey><DrugSynonyms><Name><Value>elafin</Value></Name><Name><Value>recombinant leukocyte elastase/proteinase-3 inhibitor (iv, inflammation), Proteo Biotech</Value></Name><Name><Value>tiprelestat</Value><Types><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1009064">Proteo Biotech AG</CompanyOriginator><CompaniesPrimary><Company id="1009064">Proteo Biotech AG</Company><Company id="1031967">Minapharm Pharmaceuticals</Company></CompaniesPrimary><CrossReferences><SourceEntity id="50848" type="Drug"><TargetEntity id="307882" type="siDrug">Tiprelestat</TargetEntity></SourceEntity><SourceEntity id="1009064" type="Company"><TargetEntity id="5000053784" type="organizationId">Proteo Biotech AG</TargetEntity></SourceEntity><SourceEntity id="1031967" type="Company"><TargetEntity id="4297293802" type="organizationId">Minapharm Pharmaceuticals SAE</TargetEntity></SourceEntity><SourceEntity id="1489" type="ciIndication"><TargetEntity id="D055370" type="MeSH"></TargetEntity><TargetEntity id="-197132616" type="omicsDisease"></TargetEntity><TargetEntity id="3196" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3510" type="ciIndication"><TargetEntity id="I27.0" type="ICD10"></TargetEntity><TargetEntity id="10064911" type="MEDDRA"></TargetEntity><TargetEntity id="182090" type="ORPHANET"></TargetEntity><TargetEntity id="2543" type="siCondition"></TargetEntity><TargetEntity id="244" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3645" type="ciIndication"><TargetEntity id="10051624" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"></TargetEntity><TargetEntity id="D007239" type="MeSH"></TargetEntity><TargetEntity id="-367065996" type="omicsDisease"></TargetEntity><TargetEntity id="799" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="234" type="Action"><TargetEntity id="421" type="Mechanism">Neutrophil Elastase (Leukocyte Elastase) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="9336" type="Action"><TargetEntity id="5693" type="Mechanism">Myeloblastin (PRTN3, PR3) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01998" type="ciTarget"><TargetEntity id="15489140319913" type="siTarget">Neutrophil elastase</TargetEntity><TargetEntity id="-1379720244" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-02152" type="ciTarget"><TargetEntity id="190862974956573" type="siTarget">Myeloblastin</TargetEntity><TargetEntity id="4524" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1489">Lung injury</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="3510">Pulmonary artery hypertension</Indication><Indication id="515">Transplant rejection</Indication><Indication id="746">Infectious disease</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="3645">Cardiac reperfusion injury</Indication></IndicationsSecondary><ActionsPrimary><Action id="9336">Leukocyte proteinase-3 inhibitor</Action><Action id="234">Leukocyte elastase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-30T09:37:51.000Z</LastModificationDate><ChangeDateLast>2019-04-10T00:00:00.000Z</ChangeDateLast><AddedDate>2004-07-15T16:56:48.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1009064" linkType="Company"&gt;Proteo Biotech&lt;/ulink&gt;,  and licensee &lt;ulink linkID="1031967" linkType="Company"&gt;Minapharm Pharmaceuticals&lt;/ulink&gt;, are developing tiprelestat (elafin), a recombinant inhibitor of leukocyte elastase and proteinase-3 using  &lt;ulink linkID="1021123" linkType="Company"&gt;ARTES Biotechnology&lt;/ulink&gt; yeast strain, for the potential iv/sc treatment of inflammation, transplant rejection, ischemia reperfusion injury and pulmonary arterial hypertension (PAH)   [&lt;ulink linkID="549063" linkType="Reference"&gt;549063&lt;/ulink&gt;], [&lt;ulink linkID="574747" linkType="Reference"&gt;574747&lt;/ulink&gt;], [&lt;ulink linkID="970007" linkType="Reference"&gt;970007&lt;/ulink&gt;], [&lt;ulink linkID="1355989" linkType="Reference"&gt;1355989&lt;/ulink&gt;], [&lt;ulink linkID="2136253" linkType="Reference"&gt;2136253&lt;/ulink&gt;]. Proteo Biotech is also investigating the drug for the potential treatment of   infectious disease  and for the potential prevention of ventilator induced lung injury in premature babies [&lt;ulink linkID="779075" linkType="Reference"&gt;779075&lt;/ulink&gt;], [&lt;ulink linkID="1354724" linkType="Reference"&gt;1354724&lt;/ulink&gt;],    [&lt;ulink linkID="1560464" linkType="Reference"&gt;1560464&lt;/ulink&gt;], [&lt;ulink linkID="2055528" linkType="Reference"&gt;2055528&lt;/ulink&gt;],  [&lt;ulink linkID="2129977" linkType="Reference"&gt;2129977&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2008, a  phase II trial for inflammation following esophagectomy began [&lt;ulink linkID="964095" linkType="Reference"&gt;964095&lt;/ulink&gt;]; in January 2013, data were reported [&lt;ulink linkID="1355989" linkType="Reference"&gt;1355989&lt;/ulink&gt;]. By April 2010, a phase II trial for inflammation in kidney transplant patients was initiated  [&lt;ulink linkID="1093304" linkType="Reference"&gt;1093304&lt;/ulink&gt;]; in August 2012, development was ongoing [&lt;ulink linkID="1316889" linkType="Reference"&gt;1316889&lt;/ulink&gt;]. In March 2019, a phase I trial was initiated with  sc formulation of Elafin for PAH [&lt;ulink linkID="2136253" linkType="Reference"&gt;2136253&lt;/ulink&gt;]. In November 2014, the company expected to conduct a  pivotal clinical trial  for the prophylactic treatment of acute postoperative complications after resection of esophageal cancer, followed by a scientific advice from CHMP [&lt;ulink linkID="1614855" linkType="Reference"&gt;1614855&lt;/ulink&gt;], [&lt;ulink linkID="1057304" linkType="Reference"&gt;1057304&lt;/ulink&gt;]; in February 2019,  the pivotal trial   was in preparation [&lt;ulink linkID="2123516" linkType="Reference"&gt;2123516&lt;/ulink&gt;]. In November 2015, the company with &lt;ulink linkID="20679" linkType="Company"&gt;Standford University&lt;/ulink&gt; were  invited for a pre-IND meeting by the FDA for initiating  clinical trials for PAH  [&lt;ulink linkID="2073749" linkType="Reference"&gt;2073749&lt;/ulink&gt;].  In September 2018, development was ongoing for inflammation, PAH, ventilator-induced lung injury in premature babies, lung transplantation, vascular damage and life-threatening infections 	[&lt;ulink linkID="2073749" linkType="Reference"&gt;2073749&lt;/ulink&gt;]. In March 2007, the company was seeking to outlicense the drug for selected indications [&lt;ulink linkID="779075" linkType="Reference"&gt;779075&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was previously in development for use in bypass surgery after a heart attack; a phase II trial in this setting began in April 2011 [&lt;ulink linkID="2129970" linkType="Reference"&gt;2129970&lt;/ulink&gt;]. Negative data were reported in March 2015 [&lt;ulink linkID="1647940" linkType="Reference"&gt;1647940&lt;/ulink&gt;], and no further development was reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In March 2013, the FDA granted Orphan drug status for prevention of inflammatory complications of transthoracic esophagectomy [&lt;ulink linkID="1394049" linkType="Reference"&gt;1394049&lt;/ulink&gt;], [&lt;ulink linkID="1395547" linkType="Reference"&gt;1395547&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, the FDA granted Orphan drug status for pulmonary arterial hypertension [&lt;ulink linkID="1354724" linkType="Reference"&gt;1354724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2007, the EC granted Orphan Drug status for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [&lt;ulink linkID="779075" linkType="Reference"&gt;779075&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2009, the COMP of the EMEA recommended Orphan Drug status  for esophagus carcinoma [&lt;ulink linkID="1056283" linkType="Reference"&gt;1056283&lt;/ulink&gt;], [&lt;ulink linkID="1057304" linkType="Reference"&gt;1057304&lt;/ulink&gt;]. In February 2010, the EC granted  Orphan Drug status for esophagus carcinoma [&lt;ulink linkID="1073325" linkType="Reference"&gt;1073325&lt;/ulink&gt;].	&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In November 2014, the company   received scientific advice  from the CHMP at the EMA for conducting a pivotal phase III clinical trial (POSTCOM TRIAL) with elafin for the prophylactic treatment of acute postoperative complications after resection of esophageal cancer  [&lt;ulink linkID="1614855" linkType="Reference"&gt;1614855&lt;/ulink&gt;], [&lt;ulink linkID="1642755" linkType="Reference"&gt;1642755&lt;/ulink&gt;]. In February 2019, the European pivotal trial   was in preparation following the    final European Medicines Agency advice letter [&lt;ulink linkID="2123516" linkType="Reference"&gt;2123516&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2012, University of Edinburgh received approvals for an EMPIRE sub-study in  10 healthy volunteers to have a magnetic resonance imaging (MRI) scan, a feraheme infusion and a second MRI scan 24 hours later,  to aid the interpretation of the imaging findings in the EMPIRE patients [&lt;ulink linkID="2129982" linkType="Reference"&gt;2129982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, the &lt;ulink linkID="20572" linkType="Company"&gt;University of Edinburgh&lt;/ulink&gt; and Proteo Biotech  were  planning a clinical trial to test tiprelestat for use in bypass surgery after a heart attack [&lt;ulink linkID="1093304" linkType="Reference"&gt;1093304&lt;/ulink&gt;]. In February 2011, the placebo-controlled, double-blinded phase II study was  approved by the responsible Ethics Committee of NHS Scotland. The study was to enroll  80 patients [&lt;ulink linkID="2129970" linkType="Reference"&gt;2129970&lt;/ulink&gt;].  In August 2011, the monocentric phase II Elafin Myocardial Protection from Ischaemia Reperfusion Injury study (EMPIRE) was initiated with recruting first two patients [&lt;ulink linkID="2129975" linkType="Reference"&gt;2129975&lt;/ulink&gt;]; by September 2011, the study (EMPIRE) had began in patients (n = 80) with  ischaemia reperfusion injury [&lt;ulink linkID="1355989" linkType="Reference"&gt;1355989&lt;/ulink&gt;]. In June 2012, planned interim safety analysis from the trial were completed and reported. A total of 50% of patients were enrolled in the trial. No safety concerns were raised by the Data Monitoring Committee and the continuation of the trial was recommended [&lt;ulink linkID="2129980" linkType="Reference"&gt;2129980&lt;/ulink&gt;]. In December 2012, the trial enrolled 75% of patients [&lt;ulink linkID="2129982" linkType="Reference"&gt;2129982&lt;/ulink&gt;]. In November 2013, patient recruitment and treatment was completed in the 87-patient trial. The pre-operative treatment was well-tolerated. At that time, top-line data were expected in the first quarter of 2014 [&lt;ulink linkID="1497872" linkType="Reference"&gt;1497872&lt;/ulink&gt;]. In November 2014, final data from the randomized phase II trial were reported. Data demonstrated that the drug had a favorable safety profile with significant reduction in troponin I plasma concentrations by 41% within the first 6h.  Additional beneficial effect was observed on the protection of heart muscle tissue, when elafin was present in the blood for longer time [&lt;ulink linkID="1614855" linkType="Reference"&gt;1614855&lt;/ulink&gt;]. In March 2015, further clinical data were presented at the 64th American College of Cardiology Annual Scientific Sessions in San Diego, CA. Elafin infusion resulted in &amp;gt;50% reduction in plasma elastase activity, but this did not reduce myocardial injury over 48 h when compared with placebo. Elafin did not show any effect on rates of peri-operative myocardial infarction or inflammation [&lt;ulink linkID="1647940" linkType="Reference"&gt;1647940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, data from a phase II trial for the treatment of postoperative inflammatory reactions in esophagus carcinoma  were reported. Elafin, administered as an iv formulation, demonstrated a positive effect on the period of recovery, whereby 63% patients that received the drug required only one day of intensive care. The patients in the placebo group needed several days of postoperative intensive medical care  [&lt;ulink linkID="2129977" linkType="Reference"&gt;2129977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2011, licensee Minapharm  had initiated a phase II clinical trial of elafin in kidney transplantation patients for the prevention of acute organ rejection and chronic graft injury (allograft nephropathy)   [&lt;ulink linkID="2129977" linkType="Reference"&gt;2129977&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In December 2008, Proteo and Minapharm received approval for an Egyptian phase II trial of tiprelestat in kidney transplant patients. The randomized, double-blinded, placebo-controlled study, to be conducted at the University of Cairo, would assess tiprelestat's effect on the suppression of inflammatory processes that occur after transplantation and contribute to organ rejection and accelerated aging of the transplanted organ [&lt;ulink linkID="970007" linkType="Reference"&gt;970007&lt;/ulink&gt;]; this trial was underway by April 2010 [&lt;ulink linkID="1093304" linkType="Reference"&gt;1093304&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2008, the German Federal Institute For Drugs And Medical Devices (BfArM) had approved phase II clinical trial initiation [&lt;ulink linkID="2130016" linkType="Reference"&gt;2130016&lt;/ulink&gt;]. In November 2008, a phase II trial began. The German, randomized, blinded, placebo-controlled study would assess the anti-inflammatory effects of iv tiprelestat in patients with esophagus carcinoma undergoing esophagectomy [&lt;ulink linkID="964095" linkType="Reference"&gt;964095&lt;/ulink&gt;]. In April 2010, patient recruitment was completed and preliminary data on the efficacy were expected 'shortly'. At that time, the company planned begin a further study  by  the end of 2010[&lt;ulink linkID="1093304" linkType="Reference"&gt;1093304&lt;/ulink&gt;]. In January 2013, positive data were reported. 63% of the patients treated with the drug required only one day of intensive care whereas the placebo group needed several days of postoperative intensive medical care [&lt;ulink linkID="1355989" linkType="Reference"&gt;1355989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In May 2018, a &lt;ulink linkID="20567" linkType="Company"&gt;Duke University&lt;/ulink&gt;-sponsored, multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded phase I trial (&lt;ulink linkID="339317" linkType="Protocol"&gt;NCT03522935&lt;/ulink&gt;; 42336) was planned to begin in March 2019, in the US, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sc elafin in healthy adult subjects (expected n = 30) and to identify the maximum tolerable dose (MTD) for the treatment of PAH. At that time, the trial was expected to complete in May 2019 [&lt;ulink linkID="2136582" linkType="Reference"&gt;2136582&lt;/ulink&gt;]. In February 2019, a phase I trial for PAH, was planned in the US with subcutaneously  elafin  in 2019 [&lt;ulink linkID="2123516" linkType="Reference"&gt;2123516&lt;/ulink&gt;]. In March 2019, the Duke University early phase research unit had initiated the trial in healthy volunteers in the US, to assess the safety and tolerability of repeated single doses of Elafin [&lt;ulink linkID="2136253" linkType="Reference"&gt;2136253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, data of a phase I trial were reported, whereby elafin, administered as an intravenous formulation, showed a positive tolerability [&lt;ulink linkID="2129977" linkType="Reference"&gt;2129977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, some clinical research activities, presumed to include phase I studies, were transferred to Egypt [&lt;ulink linkID="821251" linkType="Reference"&gt;821251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, Proteo  began a phase I trial of  tiprelestat. The study was approved by the German Federal Institute for pharmaceuticals and medical products, and would assess tolerability, safety, pharmacokinetic and dynamics of the drug in 32 healthy volunteers [&lt;ulink linkID="637119" linkType="Reference"&gt;637119&lt;/ulink&gt;]. In December 2005, trial data were reported. Tiprelestat was well tolerated with no adverse events  [&lt;ulink linkID="640387" linkType="Reference"&gt;640387&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, preclinical studies were completed and clinical trials were being scheduled [&lt;ulink linkID="549063" linkType="Reference"&gt;549063&lt;/ulink&gt;]. In April 2005, clinical testing was to start after manufacture of the drug was completed in  July 2005 [&lt;ulink linkID="595048" linkType="Reference"&gt;595048&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2018, preclinical data were published. Data demonstrated that the elafin treatment inhibited elastase, preserved lung pEGFR and Klf4, and attenuated apoptosis  as seen with  lungs of vehicle-treated mice [&lt;ulink linkID="2055449" linkType="Reference"&gt;2055449&lt;/ulink&gt;], [&lt;ulink linkID="2055195" linkType="Reference"&gt;2055195&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, preclinical data were published. Data demonstrated that the recombinant human  elafin treatment in mouse pups that had been exposed to 85% O2, prevented the changes during oxygen-induced damage by inhibiting elastase and the TGF-β1 signalling cascade for preventing O2-induced lung injury in neonates [&lt;ulink linkID="2055528" linkType="Reference"&gt;2055528&lt;/ulink&gt;], [&lt;ulink linkID="2056136" linkType="Reference"&gt;2056136&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, the company with Standford University were invited for a pre-IND meeting by the US FDA, to discuss the development plan for Elafin in the treatment of PAH after major advances in preclinical research  [&lt;ulink linkID="2073749" linkType="Reference"&gt;2073749&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, preclinical data were published. Data demonstrated that the drug in combination with cyclosporin A displayed synergist effect on graft oxygenation in a mouse tracheal transplant model. This effect was observed by the prevention of cyclosporine A induced tissue damage and in addition by the complementary inhibitory effects of both drugs on the innate and the adaptive immune responses. It was found that  the suppression of neutrophil elastase activity  represented an  adjunctive therapy for transplant recipients suffering acute rejection. Elafin promoted angiogenesis through activation of the extracellular signal-regulated kinase  signaling pathway but was insufficient as a single agent to completely prevent tissue ischemia during acute rejection episodes. In combination with cyclosporine, the drug effectively preserved airway microvascular perfusion and oxygenation [&lt;ulink linkID="1642774" linkType="Reference"&gt;1642774&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, data demonstrated that the drug attenuated fully developed pulmonary arterial hypertension in an animal model with a pronounced and significant improvement of the vascular pathology, parameters of pulmonary hemodynamics and right ventricular function. &lt;/para&gt;&lt;para&gt;In December 2011, preclinical data of studies conducted by  Proteo, in collaboration with Standford University, were reported. In an animal model of pulmonary arterial hypertension, it was observed that elafin attenuated the development of the typical vascular lesions for this disease. In addition, in other studies, elafin (administered as an intratracheal formulation) attenuated lung structural abnormalities noted in mechanically ventilated newborn mice. At that time, Proteo and the University planned to initiate further preclinical studies to evaluate the drug for lung diseases, including pulmonary artery hypertension, ventilator-induced injury of the immature lung and chronic lung transplant rejection [&lt;ulink linkID="2129977" linkType="Reference"&gt;2129977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, preclinical data were reported.  Elafin was able to abrogate lipopolysaccharide-induced production of monocyte chemotactic protein 1 in monocytes by inhibiting AP-1 and NFkappaB activation and the inhibition of two key inflammatory pathways confirms the importance of Elafin as a mediator of the innate immune response [&lt;ulink linkID="2130010" linkType="Reference"&gt;2130010&lt;/ulink&gt;], [&lt;ulink linkID="2130588" linkType="Reference"&gt;2130588&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, preclinical data were reported. In mice immune defense was enhanced. More antibodies were produced as well as an increased number of antigen-presenting cells of the immune system. Elafin reduces tissue damage in the lung by inflammation and influence an infection of the lung by strengthening the body's own immune defence. Infections of the lung during chronic obstructive lung disease, particularly in smoker's lungs, are frequent complications and cause an acute aggravation of the disease [&lt;ulink linkID="2130008" linkType="Reference"&gt;2130008&lt;/ulink&gt;], [&lt;ulink linkID="2130116" linkType="Reference"&gt;2130116&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, preclinical data on tiprelestat were released. Tiprelestat reduced damage to heart muscles caused by blood supply deficiencies. Administration of tiprelestat to rodents at high doses over a long period caused no toxic reactions [&lt;ulink linkID="549063" linkType="Reference"&gt;549063&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2007, Proteo entered into an agreement with &lt;ulink linkID="1031967" linkType="Company"&gt;Minapharm&lt;/ulink&gt;, via its subsidiary Rhein Minapharm Biogenetics. Minapharm was granted an exclusive license to develop, produce and market tiprelestat in Egypt, and certain Middle Eastern and African territories, and would be responsible for clinical research funding in the regions. Proteo was eligible to receive an upfront fee, milestone payments, and royalties based on any sales. This agreement augments the transfer of the biotechnological production process for the drug to Egypt [&lt;ulink linkID="821251" linkType="Reference"&gt;821251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, the EMA's Pediatric Committee (PDCO) agreed on a product-specific waiver for the drug, recommending   the submission of pediatric clinical data on esophageal carcinoma be waived in all subsets of the pediatric population [&lt;ulink linkID="1722938" linkType="Reference"&gt;1722938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, preclinical data suggested that the drug had potential application for cardiac infarction, post-injury inflammation, and transplant rejection prevention [&lt;ulink linkID="549063" linkType="Reference"&gt;549063&lt;/ulink&gt;]. In December 2005, Proteo believed  the drug would have potential therapeutic effects for inflammatory circulatory and lung disorders [&lt;ulink linkID="640387" linkType="Reference"&gt;640387&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-11-17T00:00:00.000Z</StatusDate><Source id="964095" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031967">Minapharm Pharmaceuticals</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-23T00:00:00.000Z</StatusDate><Source id="1093304" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031967">Minapharm Pharmaceuticals</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-09T00:00:00.000Z</StatusDate><Source id="821251" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-28T00:00:00.000Z</StatusDate><Source id="2136582" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1395547" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1489">Lung injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-06T00:00:00.000Z</StatusDate><Source id="2129977" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-29T00:00:00.000Z</StatusDate><Source id="779075" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-22T00:00:00.000Z</StatusDate><Source id="1560464" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3645">Cardiac reperfusion injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009064">Proteo Biotech AG</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-09T00:00:00.000Z</StatusDate><Source id="821251" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3645">Cardiac reperfusion injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-08-16T00:00:00.000Z</StatusDate><Source id="2129975" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009064">Proteo Biotech AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-28T00:00:00.000Z</StatusDate><Source id="1354724" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-04-15T00:00:00.000Z</StatusDate><Source id="549169" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009064">Proteo Biotech AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-11-24T00:00:00.000Z</StatusDate><Source id="637119" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031967">Minapharm Pharmaceuticals</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-09T00:00:00.000Z</StatusDate><Source id="970007" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009064">Proteo Biotech AG</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-09T00:00:00.000Z</StatusDate><Source id="821251" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031967">Minapharm Pharmaceuticals</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-09T00:00:00.000Z</StatusDate><Source id="821251" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009064">Proteo Biotech AG</OwnerCompany><Country id="US">US</Country><Indication id="188">Inflammatory disease</Indication><AwardedIndication>Prevention of inflammatory complications of transthoracic esophagectomy</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</MileStoneDate><Source id="1394049" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009064">Proteo Biotech AG</OwnerCompany><Country id="US">US</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-28T00:00:00.000Z</MileStoneDate><Source id="1354724" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009064">Proteo Biotech AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-20T00:00:00.000Z</MileStoneDate><Source id="779075" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009064">Proteo Biotech AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-07T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01998"><Name>Leukocyte elastase</Name><SwissprotNumbers><Swissprot>P08246</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02152"><Name>Leukocyte proteinase-3</Name><SwissprotNumbers><Swissprot>P24158</Swissprot><Swissprot>Q61096</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1021123">Artes Biotechnology</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1031967">Minapharm Pharmaceuticals</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1089880">Proteo Inc</Company><CountAsPrincipalActive>6</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>6</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>11</CountTotal></Company><Company><Company id="14841">Biotechnology Development Corp</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18438">Medical Research Council</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20525">University of Alberta</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20572">University of Edinburgh</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20679">Stanford University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="22239">Humboldt University of Berlin</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24293">German Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="15">Drug - CRADA</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="110032" title="Minapharm to develop Proteo's elafin in Egypt, certain Middle Eastern and African territories"></Deal><Deal id="124376" title="Proteo to use ARTES yeast strain to produce elafin worldwide  "></Deal><Deal id="130289" title="University of Edinburgh to study the effects of Proteo's clinical trial of elafin against cardiac muscle after coronary bypass  "></Deal><Deal id="130929" title="Proteo Biotech to provide the USAMRIID with elafin for development of anti-infectives"></Deal><Deal id="149512" title="BDC to fund the clinical study of Proteo Biotech's Elafin against acute postoperative inflammatory complications "></Deal><Deal id="153143" title="Charite Berlin to evaluate Proteo Biotech's Elafin against new indications "></Deal><Deal id="160988" title="German Government to award Proteo Biotech funding to develop a new formulation of Proteo's Elafin against chronic diseases     "></Deal><Deal id="164507" title="Funding to advance the development of Tiprelestat (Elafin) for acute postoperative inflammatory complications after resection of esophageal cancer"></Deal><Deal id="254214" title="University of Alberta to develop Proteo's Elafin for pulmonary diseases in neonates"></Deal><Deal id="254215" title="Proteo and Stanford University to conduct preclinical studies on Elafin for PAH"></Deal><Deal id="254216" title="NHLBI to award Stanford School of Medicine funding to study Elafin for pulmonary arterial hypertension, ventilator-induced lung injury and lung transplant rejections"></Deal><Deal id="254218" title="Artes Biotechnology to market Proteo Biotech's Elafin in India, Egypt and Argentina"></Deal><Deal id="254225" title="Medical Research Council to award University of Edinburgh funding for phase-II study of Elafin against Ischaemia Reperfusion Injury "></Deal></Deals><PatentFamilies><PatentFamily id="1069790" number="WO-2006122404" title="Trappin-2 (Elafin) inhibits HIV"></PatentFamily><PatentFamily id="1559666" number="WO-2011107505" title="Novel uses of elafin"></PatentFamily><PatentFamily id="1639466" number="WO-2012082056" title="Novel biomarker and uses thereof in diagnosis, treatment of autism"></PatentFamily><PatentFamily id="3139399" number="WO-2016030323" title="Use of elafin for disorders associated with elastase independent increase in troponin"></PatentFamily><PatentFamily id="4405201" number="WO-2019040528" title="Elafin incorporated biomaterials for the treatment of chronic tissue ulcers"></PatentFamily><PatentFamily id="791908" number="WO-2008127355" title="Chemorepulsion of cells"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celtaxsys Inc" id="1040618"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Autism Biodiagnosis Ltd" id="1071031"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Proteo Inc" id="1089880"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Canadian Government" id="15300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Edinburgh" id="20572"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Manitoba" id="20614"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rockefeller University" id="20670"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stanford University" id="20679"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>